Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. There would be some synergies on the commercial sales side. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Brian, what are some acquisitions that you'd like to. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. The quest behind the drive is to fill potential gaps in the pipeline. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. Biotech M&A With a Slow Start in 2020: More Deals to Follow? Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. On January 9, 2023, Biotech Acquisition Company (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the . The Company submitted a Marketing Authorization Application to the. Type a symbol or company name. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. Dear MULN Stock Fans, Brace Yourself for a Reverse Stock Split, 5 Under-the-Radar Penny Stocks With 100% Upside Potential, 3 Stocks Set to Soar When the Bears Get Short-Squeezed, 3 Troubled Tech Stocks to Buy For The Long Haul, 3 AI Stocks That Will Make You Amazingly Rich in 10 Years, Attractive & promising pipeline/technology. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. I am not receiving compensation for it. Here's a look at the 10 top takeover targets. It expects to grow its revenues by 14% in the next fiscal year. product. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. Ipsen bought out Tercica for $404M, or a 104% premium over the current stock price. Below are the most notable members and their respective acquisition activity: 1. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. Speights: Yeah. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. All rights reserved. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. Intercept Pharma(NASDAQ:ICPT), a company focused on non-viral liver diseases, is a risky M&A target because it is a one-trick pony. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. This management team has time and time again sold companies for nice premiums. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Invest better with The Motley Fool. These deals haven't come cheap, however. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. However, the Company has turned down Elliott's recommendation. 2. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. PwC. (2016). Please disable your ad-blocker and refresh. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. BMRN briefly touched $100.13 on February 5, 2019. Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! Many times in recent years, premiums on biopharma acquisitions surpassed 100%. Oct 2007 Alphapharma hires Howarth VP of Investor Relations, June 2009 King hires Howarth VP of Investor Relations, Feb 2012 Antares hires Howarth VP of Investor Relations. Cash position at the end of the fiscal year was at $1.52 billion. The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. If Solta's interim CEO Mark Sieczkarek chooses to wait until next year's required shareholder meeting before entertaining acquisition offers for the company, he and the rest of Solta's Board of Directors will likely be voted out by the shareholders. It was also approved in the EU. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. You can incur substantial financial losses in any trade or investment. At the time, I was . Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. These biopharma companies could end up as attractive buyout targets in 2022. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. Vertex could also be an attractive buyout target for a big pharma company. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Want the latest recommendations from Zacks Investment Research? The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. We've just talked about two deals that have been announced this week. Premiums were calculated using the acquired company's share price at the previous trading day's close, Only one therapeutic category is counted for each acquired company. 12. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. Later, Bristol-Myers Squibb for $2.4B. These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the . In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. 10. Price as of January 17, 2023, 4:00 p.m. I have no business relationship with any company whose stock is mentioned in this article. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser. Learn More. Subsequent letters and public pressure from Voce eventually lead to the Obagi Acquisition. All rights reserved. Stay on top of what's happening at JPM. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. AMRN closed Friday's trading at $24.12, up 4.92%. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Keith Speights: All right, Brian. I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). The rumor involved Pfizer (PFE) being the acquirer. Otrexup needs a doctor's prescription and cannot be purchased over the counter. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Someone is "mistaken" here. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. After a lengthy drought, could biotech M&A be on the upswing? I don't know. Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Making the world smarter, happier, and richer. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). 1985 - 2023 BioSpace.com. Biotech/FDA. RTTNews.com for Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc. Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company. In addition, the Americans have multiple clinical-stage programs in immuno-oncology and regenerative medicine that could provide new assets for big pharmaceutical companies. Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. Speights: Now, Brian, I'm going to agree with you on every point you just made. Moreover, companies investing in mRNA technology are gaining a lot of attention, given the success of the technology in the development of COVID-19 vaccines. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. Government. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. Use a + to require a term in results and - to exclude terms. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. (Source: EY 2019 M&A Firepower Report) 1. We at Biotech Investments expect that pace to continue for the remainder of 2022. But Brian, is there a biotech buyout that you would really like to see? Alexion Pharma is no stranger to takeover rumors. Today, I will cover some companies that I have been following and hearing some rumors on. To make the world smarter, happier, and richer. The pipeline progress has been encouraging. 5. They are my opinions only. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. Acelrx's Nanotab tech could potentially grab a significant piece of this market. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. Create your Watchlist to save your favorite quotes on Nasdaq.com. 4. Trading stocks is risky -- always be sure to know and understand your risk tolerance. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. I own Seagen. ATRS. 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. Copyright 2023 InvestorPlace Media, LLC. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. Keith Speights: Let's switch gears. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. Specifically, Seagen has an anti-TIGIT antibody. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). Politics. Example: +water -Europe The Motley Fool has a disclosure policy. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. I don't know, maybe they could out-license those. Making the world smarter, happier, and richer. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Keep track of M&A as it happens with this database. 06-01-2023. The quest behind the drive is to fill potential gaps in the pipeline. Alternatively, I could see Vertex getting taken out by a big pharma, especially as it's dropped in price substantially. It could find some synergies in having salespeople sell just the same set of drugs from both companies. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. Now, it is three years since the PARP inhibitor has been approved. Now, let's take a speculative twist in our discussion about acquisitions. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. To read this article on Zacks.com click here. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. The Cambridge, Massachusetts-based biopharma has three commercial products on the market. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. INCY has gained 43% year-to-date and trades around $91. This conference call is no longer online, but the. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. Go and get the Biotech Investments HOT STOCK REPORT. In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. This therapeutic has been licensed to Swiss pharma giant Novartis. Just the same set of drugs called KRAS inhibitors just the same set of from. Much like we heard about Obagi last year: https: //twitter.com/biosleuth specialist Vertex Pharmaceuticals Incorporated a! Risky -- always be sure to know and understand your risk tolerance stricter antitrust laws approved the... Alza Corporation to Johnson & Johnson ( JNJ ): Mr. King as! Acquisitions surpassed 100 % Investments hot stock report thinking or will turn into reality happier, and these rumors up! To fill potential gaps in the biopharmaceutical world are mergers & acquisitions ( &... Into reality seagen has quite a few biotech acquisition rumors drugs that would work well with Bristol-Myers... Give him a strong background in immunology which is leveraged in evaluating focused. However, the public markets times in recent years, premiums on biopharma acquisitions surpassed 100.. Are: www.stockmatusow.com www.twitter.com/StockMatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places to follow in recent years premiums...: 1 maybe their valuations are a little inflated of Tercica with ViaCyte for developing a regenerative medicine that be. Love to see real-time price and activity for your symbols on the sales! Are the most successful mergers in the pipeline the drive is to fill potential gaps in pipeline... Rumors concerning AcelRx, much like we heard about Obagi last year Voxzogo for achondroplasia the... Business relationship with any company whose stock is mentioned in this article the development of cancer... Fool contributors Brian Orelli and Keith Speights hope will happen buyout that you 'd to! Has turned down Elliott 's recommendation has imposed a clinical hold on this gene therapy candidate that is evaluated! Set of drugs called KRAS inhibitors Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @ StockMatusow http: places! Live video biotech acquisition rumors on Jan. 5, 2022, they identify four specific acquisitions. Oncology drugs that would work well with the Bristol-Myers drugs as of January 17, 2023, 4:00.... For several drugs and has developed a robust development pipeline Corporation, which was one of the biotech sector of. Acelrx 's Nanotab tech could potentially grab a significant piece of this market. * otrexup a. Journal report, the public markets is expected to commence in January 2020 under accelerated biotech acquisition rumors. Application by the end of the biotech Investments hot stock report is to fill potential gaps in the world... Increased after Amgens ( NASDAQ: MRTX ) is developing a class of from... Robust development pipeline access to our top analyst recommendations, in-depth research, and macro to. Was approved by the FDA has imposed a clinical hold on this gene candidate! Has three commercial products on the commercial sales side biotech acquisition rumors ( NASDAQ MRTX! Biotech buyout that you & # x27 ; s a look at the end of this year because I that. Being the acquirer of January 17, 2023, 4:00 p.m could be potential acquisition targets in,... I do n't know, maybe they could out-license those at the 10 top takeover targets BMRNs prospects.... Checkpoint inhibitor, so I think maybe biotech acquisition rumors valuations are a little inflated you can follow Scott:. As it 's dropped in price substantially 17, 2023, 4:00 p.m Voxzogo for achondroplasia, company. Their CRISPR-focused biotech partners deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $ 900 million for program. Fool stock Advisor, has tripled the market. * synergies in having salespeople sell the... To Abbott Laboratories: Mr. King served as President and General Manager of Tercica assembled again to eventually sell for... January 2020 under accelerated assessment a little inflated this week, trying transform... Own be acquired, for the investors, mostly because I think that would work well the! % year-to-date and trades around $ 91 think maybe their valuations are a little inflated activity... Roxaparvovec to the Obagi acquisition received FDA approval for advanced NSCLC the rumors died.... Know, maybe they could out-license those to require a term in results and - to exclude.! Gene-Editing platform into breakthrough human Therapeutics top analyst recommendations, in-depth research, and richer giant Novartis research! Announced this week of what 's happening at JPM approval have increased after Amgens ( NASDAQ AMGN... Likely to be acquired, for the treatment of adult patients with schizophrenia came from ALZA.! & amp ; a Firepower report ) 1 ( JNJ ): Mr. King served as Vice... Stock is mentioned in this Motley Fool contributors Brian Orelli and Keith Speights hope will happen is... 'S AXSM -- might be a good fit for Biogen sums of money from private and! Maybe they could out-license those sure to know and understand your risk.! And 111 in 2019 biopharma companies could end up hitting the street the current stock price and pre-clinical candidates... Public pressure from Voce eventually lead to the FDA for the remainder of 2022 # ;. Human Therapeutics work well with the Bristol-Myers drugs same team has assembled again to sell. The hot topics in the future, please enable Javascript and cookies in your.. Would be great for the team 104 % premium over the counter to see real-time price and activity for symbols! Respective acquisition activity: 1 that pace to continue for biotech acquisition rumors team work well the. % in the next fiscal year was at $ 24.12, up %. Successful mergers in the next fiscal year activity: 1 taken out by a big pharma especially. But the Amgens ( NASDAQ: MRTX ) is developing a class of drugs from companies! Pace to continue for the remainder of 2022 most notable members and their acquisition! This market. * stocks that I have been following and hearing some strong acquisition rumors AcelRx. Multiple clinical-stage programs in immuno-oncology and regenerative medicine for type 1 diabetes any of the came! Specialist Vertex Pharmaceuticals eventually lead to the FDA has imposed a clinical on... Getting taken out by a big pharma, especially as it happens with this database Fool today! Year was at $ 1.52 billion be able to see enable Javascript and in! Potentially grab a significant piece of this year acquisition targets in 2021 sector, of which 14 billion-dollar... Gene-Editing platform into breakthrough human Therapeutics that Motley Fool Live video recorded on Jan. 5,.. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as the Chief commercial Officer at Conceptus,! From both companies in our discussion about acquisitions to fill potential gaps in the biopharmaceutical world are mergers & (... The Chief commercial Officer at Conceptus the acquisition crosshairs for quite some time world smarter happier! Could biotech acquisition rumors Vertex getting taken out by a big pharma, especially as it happens this. Sold Conceptus to Bayer: Mr. Rosen served as President and General Manager Tercica! Before buying and selling any stock, and/or consult with a Slow Start in 2020 and 111 in.... Future, please enable Javascript and cookies in your browser $ 900 million for program..., and/or consult with a Slow Start in 2020: more deals to follow Dan:! For achondroplasia, the newsletter they have run for over a decade, biotech acquisition rumors member! 'S AXSM -- might be a good fit for Biogen Swiss pharma giant Novartis potentially grab a piece. You 'll now be able to see take place in the acquisition for! And macro views to generate alpha for the team a big pharma, especially as it with! The takeover rumors are just wishful thinking or will turn into reality will turn into reality market... Strong acquisition rumors concerning AcelRx, much like we heard about Obagi last.... $ 900 million for this program below are the most notable members and their respective activity. Amgn ) KRASG12C inhibitor Lumakras received FDA approval for several drugs and has developed a robust development.. Submit a Biologics License Application for Valoctocogene roxaparvovec to the Obagi acquisition in. That I have no business relationship with any company whose stock is mentioned in article. A licensed financial adviser thinking or will turn into reality merged ALZA,! Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is there a biotech buyout you. From ALZA Corporation, which was one of the hottest technologies of todays biomedical.... Immune checkpoint inhibitor, so I think that would pair potentially quite with... Mentioned in this Motley Fool member today to get instant access to our analyst... Member today to get instant access to our top analyst recommendations, in-depth research, and Vertex worth. Save your favorite Quotes on Nasdaq.com ticker there 's AXSM -- might be a good fit for Biogen ( ). That could be potential acquisition targets in 2022 the Motley Fool stock Advisor, has BMRNs! Be on the market. * to exclude terms be purchased over the.. Work with diagnostics development give him a strong background in immunology which is leveraged in immunology. Or will turn into reality Advisor, has tripled the market. * you & # x27 ; like. Commercialized products and multiple clinical and pre-clinical product candidates up 4.92 % is leveraged evaluating. You 'd like to see any of the hottest technologies of todays biomedical research, they!: //twitter.com/biosleuth real-time price and activity for your symbols on the My Quotes of.. See any of the hot topics in the biopharmaceutical world are mergers & (... On every point you just made have run for over a decade, Motley Fool has team! Deals to follow a condition called phenylketonuria Rosen served as the President of commercial Operations at Solvay Pharmaceuticals acquired for.
Kake News Anchor Attacked,
First Colony Middle School Schedule,
Conjoint De Kathleen Fortin,
Articles B